Compare Direxion Daily Semiconductor Bear 3X Shares (SOXS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily Semiconductor Bear 3X Shares vs TG Therapeutics Inc — how do they compare? Direxion Daily Semiconductor Bear 3X Shares trades at $43.73, while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). Which is the better fit depends on your goals.
| SOXS | TGTX | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $1.29K | $59.06 |
52-Week Low | $32.50 | $26.94 |
Market Cap | — | $8.53B |
Enterprise Value | — | $8.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOXS, the Direxion Daily Semiconductor Bear 3X ETF, declined 4.86% to $44.09 amid bearish technical signals with 18 sell indicators versus 2 buy signals. The fund benefits from semiconductor sector weakness but faces volatility due to its leveraged inverse structure. Recent corporate actions include a 1:10 stock split scheduled for July 2026 and a $0.04 dividend payment in June 2026.
The outlook remains challenging with technical indicators signaling bearish momentum. While SOXS offers tactical opportunities during semiconductor downturns, its leveraged nature poses significant risks for long-term investors. Key risks include AI hardware demand resilience and rapid market reversals that could erode value quickly.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion Daily Semiconductor Bear 3X Shares
SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
